Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preventive Healthcare Services01:30

Preventive Healthcare Services

2.3K
Preventive healthcare services keep people healthy via frequent check-ups, screening, and counseling. They primarily aid in disease prevention rather than treating an acute or chronic illness. Preventive treatment also keeps individuals productive and energetic, allowing them to work well into their retirement years. Examples of preventive care services include:
2.3K
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

375
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
375
Levels of Health Promotion and Illness Prevention01:26

Levels of Health Promotion and Illness Prevention

16.1K
Health promotion allows a person to control the determinants of health, resulting in an improved health status. It enhances the quality of life and reduces premature deaths. Health promotion and illness prevention programs help people make beneficial choices to reduce the risk of disease and disabilities. There are three health promotion and illness prevention levels: primary, secondary, and tertiary prevention.
In primary prevention, actions taken before disease onset prevent the disease from...
16.1K
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

370
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
370
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

346
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
346
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

334
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
334

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predictors of Clinical Trial Participation Among Older U.S. Adults With Multimorbidity: A Cross-Sectional Survey.

Clinical and translational science·2026
Same author

Attitudes About Clinical Trials of Medications in Older Hispanic/Latino Adults With Multimorbidity.

Journal of the American Geriatrics Society·2025
Same author

Preferences Regarding Clinical Drug Trial Elements: A Nationally Representative Survey of Older Adults With Multimorbidity.

Journal of the American Geriatrics Society·2025
Same author

Why patients fail to seek information on OTC product interactions with a direct-acting oral anticoagulant: perspectives on information-seeking.

BMC primary care·2025
Same author

"Unjustified Partiality or Impartial Bias? Reckoning with Age and Disability Discrimination in Cancer Clinical Trials".

The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics·2024
Same author

Navigating the Path to Inclusion: Understanding Barriers and Facilitators to Clinical Trial Participation Among Chinese Older Adults in the United States with Multimorbidity.

Journal of general internal medicine·2024
Same journal

Inflammation as a Fulcrum in Cardiovascular Disease: The Evolving Case for High-Sensitivity C-Reactive Protein.

Trends in cardiovascular medicine·2026
Same journal

Comment on "advancing personalised care in atrial fibrillation and stroke: The potential impact of AI from prevention to rehabilitation".

Trends in cardiovascular medicine·2026
Same journal

Response to: Comment on "Advancing personalised care in atrial fibrillation and stroke: The potential impact of AI from prevention to rehabilitation" (TCM-D-26-00198).

Trends in cardiovascular medicine·2026
Same journal

High-sensitivity C-reactive protein as a prognostic biomarker in cardiovascular diseases: implications for atherosclerosis, chronic kidney disease, and heart failure - a review.

Trends in cardiovascular medicine·2026
Same journal

The cost of false dichotomies in a dynamic disease.

Trends in cardiovascular medicine·2026
Same journal

Late-presenting ST-segment elevation myocardial infarction: is it just a matter of time? From temporal cutoffs to biological staging.

Trends in cardiovascular medicine·2026
See all related articles

Related Experiment Video

Updated: Apr 19, 2026

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

8.2K

Primary prevention: do the very elderly require a different approach?

Janice B Schwartz1

  • 1Department of Medicine, University of California, San Francisco, San Francisco, CA; Jewish Home of San Francisco, San Francisco, CA; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA.

Trends in Cardiovascular Medicine
|January 7, 2015
PubMed
Summary
This summary is machine-generated.

Cardiovascular prevention in older adults requires personalized strategies, considering life expectancy and function. Treatment decisions for hypertension, cholesterol, and aspirin must weigh individual risks and benefits for optimal health outcomes.

More Related Videos

Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing
06:58

Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing

Published on: January 24, 2020

8.0K

Related Experiment Videos

Last Updated: Apr 19, 2026

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

8.2K
Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing
06:58

Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing

Published on: January 24, 2020

8.0K

Area of Science:

  • Gerontology
  • Cardiology
  • Preventive Medicine

Background:

  • Cardiovascular prevention guidelines increasingly rely on randomized placebo-controlled trial data.
  • Such data are limited for individuals over 75-80 years, where risk-benefit profiles differ.

Purpose of the Study:

  • To review primary prevention strategies for older adults, emphasizing individualized decision-making.
  • To discuss the application of guidelines in the context of altered risk-benefit relationships in the elderly.

Main Methods:

  • Review of existing clinical trial data and guideline recommendations for cardiovascular prevention in older populations.
  • Analysis of factors influencing treatment decisions, including life expectancy, functional status, and patient preferences.

Main Results:

  • Systolic hypertension treatment is supported in older adults with ≥2-year lifespan, with adjusted goals and attention to side effects like falls.
  • Lipid-lowering with statins (HMG-CoA reductase inhibitors) for primary prevention in those >75 requires careful individual assessment due to delayed benefits and potential adverse effects.
  • Exercise interventions show multi-system benefits and should be part of preventive regimens, despite limited trial data.

Conclusions:

  • Preventive therapy in the very old necessitates considering comorbidities, polypharmacy, and altered medication risk-benefit profiles.
  • Treatment goals and approaches must be tailored to individual patient preferences and functional status across the older age spectrum.